Published by Josh White on 19th May 2026
(Sharecast News) - Avacta Group said on Tuesday that it had strengthened its position as a pure-play oncology biopharmaceutical company during 2025, with progress across its 'preCISION' tumour-activated drug delivery platform and cash runway extended into the first quarter of 2027.
URL: http://www.digitallook.com/dl/news/story/35942978/...